Abstract
The design and synthesis of a novel nuclear factor erythroid 2-related factor 2 (Nrf2) enhancer is reported. Using a structure-based virtual screening approach, several commercially available compounds were identified as having high probability to interact with the Nrf2-binding pocket in the Kelch-like ECH-associated protein 1 (Keap1). Keap1 is an adaptor protein that recruits Nrf2 to a cullin-3-dependent ubiquitin ligase complex. The identified compounds were tested against rat pheochromocytoma PC-12 cells for their cytoprotective activity, and one compound (SKT359126) demonstrated an Nrf2-mediated cell-protective effect. Based on the structure of SKT359126, 23 novel derivatives were synthesized and evaluated. Of the screened derivatives, 1-{4-[(3,4-dihydroxybenzylidene)amino]phenyl}-5-oxopyrrolidine-3-carboxylic acid demonstrated better activity than the parent molecules in activating the Nrf2 transduction pathway in a dose- and time-dependent manner. This compound represents a promising starting point for the development of therapeutics for the treatment of oxidative-stress-related diseases.
| Original language | English |
|---|---|
| Pages (from-to) | 320-333 |
| Number of pages | 14 |
| Journal | ChemPlusChem |
| Volume | 83 |
| Issue number | 5 |
| DOIs | |
| State | Published - May 2018 |
Keywords
- Nrf2
- medicinal chemistry
- oxidative stress
- oxopyrrolidine derivatives
- virtual screening
All Science Journal Classification (ASJC) codes
- General Chemistry